Whittle, , JR; Vaillant, F; Surgenor, E; Policheni, AN; Giner, G; Capaldo, BD; Chen, HR; Liu, HK; Dekkers, JF; Sachs, N; Clevers, H; Fellowes, A; Green, T; Xu, H; Fox, SB; Herold, MJ; Smyth, GK; Gray, DHD; Visvader, JE; Lindeman, GJ; ,
Although cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors significantly extend tumor response in patients with metastatic estrogen receptor-positive (ER+) breast cancer, relapse is almost inevitable. This may, in part, reflect the failure of CDK4/6 inhibitors to induce apoptotic cell death. We therefore evaluated combination therapy with ABT-199 (venetoclax), a potent and selective BCL2 inhibitor.